Site
Search results (Showing 1 - 10 of 25 results)
-
References | 22 May 2016
Factors Associated with Caregiver's Burden in Relapsing-Remitting Multiple Sclerosis and Satisfaction with Current Therapies. MS-Feeling Study.
-
References | 4 Mar 2015
[Oral treatments in multiple sclerosis].
Meca-Lallana J E, Hernández-Clares R, Carreón-Guarnizo EMed Clin (Barc). 2014 Dec; 143 Suppl 3:23-9. PMID: 25732946. Abstract -
References | 14 Jul 2015
Spasticity in multiple sclerosis and role of glatiramer acetate treatment.
Meca-Lallana J E, Hernández-Clares R, Carreón-Guarnizo EBrain Behav. 2015 Sep; 5(9):e00367. Epub 2015 Jul 14. PMID: 26445705. Abstract -
References | 22 May 2016
Cost Analysis of the Use of Glatiramer Acetate Compared to Interferon-Â in Patients with Relapsing-Remitting Multiple Sclerosis and Spasticity in Spain.
Sanchez de la Rosa R, Garcia BL, Meca Lallana JValue Health. 2014 Nov; 17(7):A394. PMID: 27200920. Abstract -
References | 8 Sep 2016
A consensus initiative for the assessment of patients newly diagnosed with multiple sclerosis in Spain: the eXamina Project.
Meca-Lallana V, Arroyo-González R, Meca-Lallana J, Martín-Hernández J, Sánchez-de la Rosa RNeurodegener Dis Manag. 2016 Sep 7. PMID: 27599780. Abstract -
References | 16 Oct 2015
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Editors' PickSánchez-de la Rosa R, García-Bujalance L, Meca-Lallana JHealth Econ Rev. 2015 Dec; 5(1):30. Epub 2015 Oct 16. PMID: 26475277. Abstract -
References | 30 Nov 2011
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sanchez O, Cano A, Costa-Frossard L, Hernández-Clares R, Sanchez-De la Rosa R, Escala Study GroupJ Neurol Sci. 2012 Apr 15; 315(1-2):123-8. Epub 2011 Nov 30. PMID: 22133480. Abstract -
References | 2 Apr 2013
Plasma Exchange for Steroid-Refractory Relapses in Multiple Sclerosis: An Observational, MRI Pilot Study.
Meca-Lallana JE, Hernández-Clares R, León-Hernández A, Genovés Aleixandre A, Cacho Pérez M, Martín-Fernández JJClin Ther. 2013 Mar 26. PMID: 23541130. Abstract -
References | 23 Mar 2013
[Biomarkers in multiple sclerosis].
Fernandez O, Arroyo-Gonzalez R, Rodriguez-Antiguedad A, Garcia-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintore M, Oreja-Guevara C, Alvarez-Cermeno JC, et al.Rev Neurol. 2013 Apr 1; 56(7):375-90. PMID: 23520007. Abstract -
References | 27 Apr 2016
[Prevalence of multiple sclerosis in the Region of Murcia].
Carreon-Guarnizo E, Andreu-Reinon E, Cerdan-Sanchez M, Carrasco-Torres R, Hernandez-Clares R, Prieto-Valiente L, Garcia-Escriba C, Sola-Roca A, Martinez-Andreu ME, Miralles Gonzalez-Conde MA, et al.Rev Neurol. 2016 May 1; 62(9):396-402. PMID: 27113063. Abstract